banner2

Getting started
EEDQ CAS 16357-59-8

EEDQ CAS 16357-59-8 - Manufacturers, Suppliers, Factory from China

EEDQ CAS 16357-59-8, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

EEDQ CAS 16357-59-8 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — EEDQ CAS 16357-59-8 N-Ethoxycarbonyl-2-Ethoxy-1,2-Dihydroquinoline Purity >99.0% (HPLC)
Read More

Saccharin Insoluble CAS 81-07-2 Purity >99.0% (HPLC)

2,3-Butanedione CAS 431-03-8 Purity >99.0% (GC)

Citric Acid Anhydrous CAS 77-92-9 Assay 99.5~100.5%

Dimethyl Dicarbonate (DMPC) CAS 4525-33-1 Purity ≥99.8% (HPLC) Food Additive Preservative

Maltol CAS 118-71-8 (3-Hydroxy-2-Methyl-4-Pyrone) Purity ≥99.0% (HPLC)

L-Menthol CAS 2216-51-5 Purity >99.5% (GC) Factory

banner4

Top Selling Products

Related Blog
Reviews

The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) -Shanghai Ruifu Chemical Co., Ltd. will attend with customers.

Shanghai Ruifu Chemical Co., Ltd. will attend the The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) with customers. The 87th China International ...
New COVID treatments offer hope

Scientists around the world have made promising breakthroughs in developing a cure for COVID-19. Among new developments include antiviral pills and antibody compounds. As more countries look to ado...
Xi presents award to top scientists

President Xi Jinping, also general secretary of the Communist Party of China (CPC) Central Committee and chairman of the Central Military Commission, presents China’s top science award to a...
The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021

The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021 As the world’s second largest medical market, ...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
Paxlovid: what we know about Pfizer's Covid-19 pill

Pfizer is seeking emergency use authorisation from the FDA for its novel Covid-19 antiviral pill Paxlovid. Share Article On the heels of Merck antiviral molnupiravir’s UK approval, Pfizer...

2022.12.28 06:47:15
2022.12.09 20:31:55
2022.08.02 21:11:33
2021.12.11 20:52:15
2021.11.27 16:42:25
2021.10.28 16:25:00

related search